Results 171 to 180 of about 11,522 (197)

Seven Strategies Implemented in Response to the 16th Ebola Virus Disease Outbreak in the Democratic Republic of Congo: Lessons Learned over a Three-Month Period. [PDF]

Viruses
Mwamba DK, Angendu KB, Diouf W, Mikobi MC, Leonard O, Kalala D, Ntumba N, Kakule D, Kayembe DK, Sana E, Kabasele B, Katya J, Montoyo A, Serra B, Bulambo H, Otshudiema J, Kapanga S, Balayulu O, Muya J, Kamangu E, Kitenge R, Tshapenda G, Kasita C, Keita M, Kabasubabo FK, Kombe J, Mossoko M, Ngandu CB, Manianga C, Moullec G, Zarowsky C, Akilimali PZ.   +31 more
europepmc   +1 more source

Ebola Death after the Announcement of the End of the Outbreak

Medisur, 2016
Lian Roque Roque, Carlos Lázaro Nodals García   +1 more
doaj  

Some of the next articles are maybe not open access.

Related searches:

Pseudotyped Viruses for Marburgvirus and Ebolavirus

2023
Marburg virus (MARV) and Ebola virus (EBOV) of the Filoviridae family are the most lethal viruses in terms of mortality rate. However, the development of antiviral treatment is hampered by the requirement for biosafety level-4 (BSL-4) containment. The establishment of BSL-2 pseudotyped viruses can provide important tools for the study of filoviruses ...
Li, Zhang, Shou, Liu, Youchun, Wang
openaire   +2 more sources

Immune Evasion in Ebolavirus Infections

Viral Immunology, 2015
Ebola virus (EBOV) infects humans as well as several animal species. It can lead to a highly lethal disease, with mortality rates approaching 90% in primates. Recent advances have deepened our understanding of how this virus is able to prevent the development of protective immune responses.
Jonathan, Audet, Gary P, Kobinger
openaire   +2 more sources

Reston Ebolavirus in Macaques

2020
Prior to the discovery of the Reston ebolavirus (RESTV) in 1989, filoviruses were thought to be present only in Africa. The virus was discovered in a quarantine facility in Reston, Virginia, USA, following the deaths of imported cynomolgus macaques (Macaca fascicularis) from the Philippines displaying severe haemorrhagic disease.
Ina L. Smith, Catalino Demetria, Shuetsu Fukushi   +2 more
openaire   +1 more source

Peptides for Anti-Ebolavirus Vaccines

Current Drug Discovery Technologies, 2016
Two main factors can affect the development of ebolavirus immunotherapeutics: the vast peptide commonality between ebolavirus and human proteins, and the high rate of spontaneous mutation of ebolavirus within its human host. Indeed, the viral versus human peptide overlap may represent a relevant source of autoimmune crossreactions following vaccination,
openaire   +2 more sources